885518-49-0

Basic information

• Product Name: 6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER
• Synonyms: 6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER;Methyl 6-bromo-(1H)-indaz...;1H-Indazole-4-carboxylic acid, 6-broMo-, Methyl ester;6-BroMo-1H-indazole-4-carboxylic acid Methyl ester;6-BroMo-1H-indazol-4-carboxylic acid Methyl ester
• CAS NO: 885518-49-0
• Molecular Formula: C₉H₇BrN₂O₂
• Molecular Weight: 255.07
• Product Categories: Indazoles
• Mol File: 885518-49-0.mol

Chemical Properties

• Boiling Point: 395.877 °C at 760 mmHg
• Flash Point: 193.22 °C
• Appearance: /
• Density: 1.71 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.21±0.40(Predicted)
• CAS DataBase Reference: 6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER(885518-49-0)
• EPA Substance Registry System: 6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER(885518-49-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 885518-49-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER is used as a building block for the synthesis of pharmaceuticals, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Synthesis:
In the agrochemical industry, 6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER is used as a key component in the creation of agrochemicals, aiding in the development of products for agricultural use.
Used in Organic Synthesis as a Reagent:
6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER is utilized as a reagent in organic synthesis to introduce the indazole group into various organic molecules, enhancing their properties and potential applications.
Used in Medicinal Chemistry Research:
6-BROMO-4-INDAZOLECARBOXYLIC ACID METHYL ESTER is employed in medicinal chemistry research to explore its potential in the development of new drugs, providing a foundation for innovative pharmaceutical advancements.

Upstream product

• 67-56-1 methanol 
• 885523-08-0 6-bromo-1H-indazole-4-carboxylic acid 
• 59382-59-1 2-methyl-3-nitro-benzoic acid methyl ester 
• 118-90-1 ortho-methylbenzoic acid 
• 79669-49-1 5-bromo-2-methylbenzoic acid 
• 1346597-55-4 methyl 1-acetyl-6-bromo-1H-indazole-4-carboxylate 
• 1000342-11-9 2-methyl-3-amino-5-bromobenzoic acid methyl ester 
• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 220514-28-3 5-bromo-2-methyl-3-nitrobenzoic acid methyl ester 
• 107650-20-4 5-bromo-2-methyl-3-nitro-benzoic acid 

Downstream Products

• 1194020-00-2 6-bromo-1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid methyl ester 
• 1244017-28-4 methyl 6-(phenylethynyl)-1H-indazole-4-carboxylate 
• 1245465-61-5 methyl 6-bromo-1-[(4-methylphenyl)sulfonyl]-1H-indazole-4-carboxylate 
• 1396772-45-4 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(4-(morpholinomethyl)phenyl)-1H-indazole-4-carboxamide 
• 1396772-66-9 1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-(3-(methylamino)propoxy)phenyl)-1H-indazole-4-carboxamide 
• 1346704-33-3 GSK343 
• 885523-89-7 6-bromo-3-iodo-1H-indazole-4-carboxylic acid methyl ester 
• 1194019-49-2 6-cyano-1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid 4-(1-methyl-piperidin-4-ylsulfamoyl)-benzylamide 
• 1194019-41-4 1-(4-fluoro-phenyl)-4-(4-methylsulfamoyl-benzylcarbamoyl)-1H-indazole-6-carboxylic acid ethyl ester 
• 1194019-43-6 1-(4-fluoro-phenyl)-4-(4-methylsulfamoyl-benzylcarbamoyl)-1H-indazole-6-carboxylic acid 
• 1194019-45-8 1-(4-fluoro-phenyl)-1H-indazole-4,6-dicarboxylic acid 6-methylamide 4-(4-methylsulfamoyl-benzylamide) 
• 1194019-27-6 1-(4-fluoro-phenyl)-6-methanesulfonyl-1H-indazole-4-carboxylic acid 4-methylsulfamoyl-benzylamide 
• 1194019-33-4 1-(4-fluoro-phenyl)-6-methylamino-1H-indazole-4-carboxylic acid 4-methylsulfamoyl-benzylamide 
• 1194019-25-4 6-cyano-1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid 4-methylsulfamoyl-benzylamide 

Relevant articles and documents

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Synthesis and evaluation of a novel series of 6-bromo-1-cyclopentyl-1H-indazole-4-carboxylic acid-substituted amide derivatives as anticancer, antiangiogenic, and antioxidant agents

A series of novel indazole derivatives has been synthesized and evaluated for anticancer, antiangiogenic, and antioxidant activities. The capability of the synthesized compounds 11a–x to hinder the viability of three human cancer cells lines, HEP3BPN 11 (liver), MDA 453 (breast), and HL 60 (leukemia), were assessed by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. Among the compounds 11a–x screened, 11c and 11d showed the higher inhibitory activity on the viability of HEP3BPN 11 (liver), when compared with the standard methotrexate. These compounds were further tested to evaluate their potential to inhibit the proangiogenic cytokines associated with tumor development. Compound 11c was found to be a potent antiangiogenic agent against TNFα, VEGF, and EGF, whereas 11d showed potent antiangiogenic activity against TNFα, VEGF, IGF1, TGFb, and leptin inhibition. All the compounds 11a–x were screened for their antioxidant activities using 2,2-diphenyl-1-picryl hydrazine (DPPH), hydroxyl (OH), and superoxide radical (SOR) scavenging activity. Compounds 11n, 11p, 11q, and 11v have shown significant OH radical scavenging activities, also compounds 11c, 11h, and 11k were found to have a DPPH radical scavenging activity and compounds 11a and 11m exhibited better SOR scavenging activity when compared with the reference compound ascorbic acid. In silico molecular docking analysis revealed important structural insights behind observed anti TNFα effect by present indazole compounds.

Pyridone derivatives and its preparation and use

The invention belongs to the field of chemical medicines, and particularly relates to a pyridone derivative, a preparation method and an application thereof. The pyridone derivative is represented as the formula (I). The invention also provides the prepar

Indazole derivatives for use in the treatment of influenza virus infection

The present invention is directed to compounds for use in the treatment or prevention of influenza virus infection.

SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS

The present invention relates to substituted 6,5 -fused bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.

4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.